U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Mycobacterium tuberculosis Complex Drug Susceptibility Testing Program: Model Performance Evaluation Program Report of Results August 2021

Public Domain


Details

  • Alternative Title:
    CDC MPEP MTBC DST Report for February 2020 Survey
  • Corporate Authors:
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination.
  • Description:
    The Model Performance Evaluation Program (MPEP) is an educational self-assessment tool in which five isolates of M. tuberculosis complex (MTBC) are sent to participating laboratories biannually for staff to monitor their ability to determine drug resistance among the isolates. It is not a formal, graded proficiency testing program. The associated report includes results for a subset of laboratories performing drug susceptibility tests (DST) for MTBC in the United States. MPEP is a voluntary program, and this report reflects data received from participating laboratory personnel. This aggregate report is prepared in a format that will allow laboratory personnel to compare their DST results with those obtained by other participants using the same methods and drugs, for each isolate. We encourage circulation of this report to personnel who are either involved with DST or reporting and interpreting results for MTBC isolates

    CDC is neither recommending nor endorsing testing practices reported by participants. For standards, participants should refer to consensus documents published by the Clinical and Laboratory Standards Institute (CLSI), “M24: Susceptibility Testing of Mycobacteria, Nocardiae spp., and Other Aerobic Actinomycetes” and “M62: Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes” [1, 2]. Additionally, World Health Organization (WHO) published two technical reports investigating critical concentrations, by method, for INH, RMP, EMB, PZA and twelve second-line anti-tuberculosis drugs [3, 4]. Based on the systematic review data, recommendations were made for adjustments to critical concentrations for RMP, MOX, LVX, AMK, and KAN for some DST methods.

  • Subjects:
  • Document Type:
    Report
  • Pages in Document:
    40 numbered pages
  • Collection(s):
  • Main Document Checksum:
    urn:sha-512:e3f765729711d5a01fe17fb67c651021cc90445fc69f45aac3dceebecc02a3216eb352dd17ec85210cb2b496f0a69bfebad8b4f5f9d90f1e05735eea9312782c
  • Download URL:
  • File Type:
    Filetype[PDF - 1.04 MB ]
PREVIOUS
ON THIS PAGE
Details
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.
BACK TO TOP